Nexipox Plus Vaccine 0.5ml Injection

The Nexipox Plus Vaccine 0.5ml Injection, manufactured by Novo Medi Sciences Pvt. Ltd., is a live attenuated vaccine indicated for active immunization against varicella, commonly known as chickenpox. This vaccine is designed to protect healthy, varicella-susceptible individuals from 12 months of age and older.

Each 0.5ml dose of the reconstituted vaccine contains the Oka strain of the varicella-zoster virus, with a potency of ≥ 2000 PFU. Nexipox Plus features an advanced 2X Trehalose-based stabilizer system, which replaces conventional stabilizers like gelatin and mannitol. This formulation enhances viral stability, preserves antigen potency, and reduces the risk of allergic reactions and antigen crystallization, making it suitable for diverse climatic conditions.

The vaccine is administered via subcutaneous injection, with the upper arm (deltoid region) being the preferred site. It is supplied as a lyophilized powder and solvent for solution for injection, requiring reconstitution with the provided sterile diluent immediately before use. Reconstituted vaccine should be discarded if not used within 30 minutes. Nexipox Plus Vaccine 0.5ml Injection must be stored in a refrigerator between +2°C to +8°C and must not be frozen.

Key Features : 

Antigen Composition: Contains live attenuated Varicella-Zoster Virus (Oka strain) ≥ 2000 PFU per 0.5ml dose.
Approved Indications and Target Population: Indicated for active immunization against varicella (chickenpox) in healthy, varicella-susceptible individuals from 12 months of age and older.
Cold-chain Storage Temperature: Requires refrigeration between +2°C to +8°C; do not freeze.
Route of Administration: Administered subcutaneously, preferably in the deltoid region of the upper arm.
Schedule / Dosing Intervals: Children (12 months to 12 years) receive two doses at least 3 months apart; Adolescents and Adults (≥13 years) receive two doses 4 to 8 weeks apart.
Reconstitution Requirements: Supplied as lyophilized powder and sterile diluent; reconstitute immediately before use and discard if not used within 30 minutes.
Regulatory Approval: Approved by the Drugs Controller General of India (DCGI) for use in individuals aged 12 months and above, backed by patented technology across 156 countries.